- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Emlidus
Empagliflozin + Linagliptin
Description:
Emlldus® is a combination of Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor & Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Emlldus® is a combination of Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor & Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Indications:
Emlldus® is indicated-
Emlldus® is indicated-
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- In adults with type 2 diabetes who have known cardiovascular disease when both Empagliflozin & Linagliptin is appropriate & Empagliflozin is needed to reduce the risk of cardiovascular death
Mode of Action:
Empagjifiozin: Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Linagliptin: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormone levels are increased in response to a meal. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and release insulin from pancreatic beta cells. Incretin hormones also lower glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.
Empagjifiozin: Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Linagliptin: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormone levels are increased in response to a meal. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and release insulin from pancreatic beta cells. Incretin hormones also lower glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.
Other Brands From Same Therapeutic Class
